Cel Sci Corporation (CVM)

[georgebailey]

@Lrock theres not much to say about the data from the first patient set other than Geert did well getting from 880 to 928 without pre approval. MK must have looked good when the continue decision was made.
Looking at MK as a buyout instead of product revenue makes our investment much easier to analyze.The arb win and the allowance of the first set to count as events was huge. My cost basis would be much lower if i understood this dynamic then.
The fact that the arb was a win, the CRO malpractice did not hurt our buyout valuation (albeit without monetary damages).It just delayed it.
Back then I thought monetary damages as problematic- you must be damaged to have an actionable suit.How do you calc damages when you have vitually no reputation and no revenue(rhetorical)?
We are in really good shape here and getting better as evidenced by stock price and institutional sponsorship increasing, buy rec....etc.